NGM Biopharmaceuticals
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.